Chemoradiation Plus Weekly c225 Against Locoregionally Advanced Nasopharyngeal Carcinoma (NPC)

Jiangsu Cancer Institute & Hospital61 enrolled

Overview

The investigators will add weekly cetuximab (c225) to the standard care of chemoradiation against locoregionally advanced Nasopharyngeal Carcinoma (NPC), and evaluate the toxicity and efficacy of this new regimen.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Nasopharyngeal Carcinoma

Interventions

Intensity-modulated radiotherapyRADIATION

Patients will be given intensity-modulated radiotherapy(IMRT)

Concurrent chemotherapy with paclitaxel and nedaplatinDRUG

Patients will be given 2 cycles of concurrent chemotherapy with paclitaxel and nedaplatin

CetuximabBIOLOGICAL

Patients will be given cetuximab weekly during radiation therapy

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Pathologically confirmed untreated NPC patients * locoregionally advanced (T3-4 or N2-3 M0) * 18-65 years * with MRI examinations * ECOG ≤ 2 * With written consent Exclusion Criteria: * Without a second cancer * Pregnancy * With other severe diseases (blood,liver ,kidney or heart diseases) * Could not be staged properly * Without written consent

Locations (1)

Jiangsu Cancer Hospital

Nanjing, Jiangsu, China

Outcomes

Primary Outcomes

Number of Participants with Adverse Events as a Measure of Safety

Time frame: 6 months

Number of Participants with Adverse Events as a Measure of Safety and tolerability

Time frame: 6 months

Secondary Outcomes

Progress free survival

Time frame: 24 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.